# A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33

> **NCT07590856** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **SmartNuclide Biopharma** · enrollment: 20 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** GPA33-CC；177Lu-SmartD2

## Key facts

- **NCT ID:** NCT07590856
- **Lead sponsor:** SmartNuclide Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07590856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07590856, "A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07590856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*